Prevention of Bone Loss After Acute SCI by Zoledronic Acid
Status:
Completed
Trial end date:
2020-08-25
Target enrollment:
Participant gender:
Summary
The overall objective of this study is to define an effective therapeutic approach, using
currently available medication, to prevent or mitigate the loss of bone mass and bone
strength that occurs after acute spinal cord injury.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborator:
United States Department of Defense
Treatments:
Bone Density Conservation Agents Diphosphonates Zoledronic Acid